New Delhi: The Subject Expert Committee (SEC) has given a recommendation to DCGI (Drugs Controller General of India) for the use of Bharat Biotech’s Covaxin for 2 to 18 age group.
The final approval will be given by DCGI. If approved, it will be the second vaccine cleared for use on children. Earlier in August, Zydus Cadilla’s three dose DNA was allowed for use on children over 12-years.
Serum institute’s Novovax is the third potential vaccine for kids. The DCGI had last month cleared it for trials on children between seven and 11 years.